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The relationship between overall survival (OS) and disease progression end points has been demonstrated in colorectal, colon, and
non-small cell lung cancers. We assessed the association between OS and time-to-progression (TTP) or progression-free survival
(PFS) in metastatic breast cancer (MBC) studies. A literature search retrieved all randomised controlled trials since 1994 in patients
with MBC in which OS and either TTP or PFS were reported. Summary data on trial and patient characteristics were abstracted.
Study effect sizes were derived as the ratio of median progression (or survival) times, which approximates the hazard ratio. Effects
were centred at zero for regression analyses weighted by sample size. Numerous treatments were represented in 67 studies (17081
patients). Modeling showed a positive association between outcomes for progression and survival (R
2¼0.30) with a slope of 0.32
(Po0.001) and a non-significant intercept. Thus, a treatment effect on TTP/PFS translated into a concordant effect on OS, but with
attenuated effect size. Similar results were found in models of subsets and sensitivity analyses. These results demonstrate that
treatment effects on progression end points in MBC trials are expected to result in treatment differences on OS that are smaller yet
consistently in the same direction.
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Most studies of anticancer agents are designed and powered to
show differences between groups on disease progression end
points such as response rates, time-to-progression, time-to-
recurrence or disease-free survival. Although increased survival
time is clearly an implicit goal, it is difficult to establish in
randomised studies when standard clinical practise is to change
treatments at the onset of new progressive events. Especially in the
metastatic setting, where expected survival time may be very short,
the use of drug combinations or sequential use of multiple drug
classes is commonplace. Increasingly, patients in clinical trials are
offered alternate treatment upon progression. Consequently, few
studies actually demonstrate an unequivocal survival benefit using
intent-to-treat analysis approaches.
In several tumour types, efforts have been made to justify the
use of alternate, more easily established end points by showing
how well they are correlated with survival. Several meta-analyses
have been published (Table 1) that show a link between time-to-
progression (TTP) or progression-free survival (PFS) with overall
survival (OS) in metastatic colorectal or non-small cell lung cancer
(Johnson et al, 2006) and colon cancer in the adjuvant setting
(Sargent et al, 2005). For breast cancer, a moderately strong
correlation between 2-year disease-free survival and 5-year overall
survival was observed in the adjuvant setting (Ng et al, 2008). A
meta-analysis of metastatic breast cancer studies found a positive
relationship between objective response and overall survival on an
individual patient basis, but the relationship was less clear when
treatment regimens were compared (Bruzzi et al, 2005). The
authors questioned whether the relationship was strong enough to
support objective response rate as a valid surrogate of survival
when comparing treatments. Articles by two groups (Hackshaw
et al, 2005; Burzykowski et al, 2008) examined the association with
survival of several potential surrogate end points, specifically in
studies of anthracyclines for advanced or metastatic breast cancer.
We performed a broad-based structured review and meta-
analysis of randomised controlled trials in metastatic breast
cancer. The objective of this research was to document and model
the relationship between time-to-disease progression and OS in
metastatic breast cancer studies across the literature.
METHODS
Study selection
Inclusion criteria for studies were determined prior to starting the
literature search. Published articles of randomised controlled trials
(RCTs) of patients with metastatic breast cancer were considered
for inclusion if they were published in English after 1994 and
reported both TTP (or PFS) and OS. Only studies in which the
entire population had metastatic breast cancer (MBC) were
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sincluded; studies that included patients with locally advanced
breast cancer were not included to avoid potential confounding.
PubMed searches were conducted using the terms ‘breast cancer,’
‘metastatic,’ and ‘survival’ combined with recognised search terms
to identify randomised controlled trials. In addition to the
electronic literature search, we reviewed bibliographic reference
lists of included studies and key review articles to identify other
studies. Titles were initially reviewed for relevance. For those
potentially meeting the inclusion criteria, the abstract was then
reviewed. Finally, for those abstracts that appeared eligible for
inclusion, full-text articles were retrieved and further examined.
Data abstraction
Data were abstracted from studies where estimates were provided for
both progression and survival outcomes. In addition to the summary
data, we abstracted definitions of the primary outcomes in each trial.
Distinctions between definitions for TTP and PFS were not
consistent. Many trials included all deaths as events for the TTP
outcome, which is more typically done for the PFS outcome. For this
reason and considering the similarity in summary data, we combined
r e s u l t sf o rt h eo u t c o m e so fT T Po rP F S .
The methodological quality of each trial was assessed by
confirming randomisation and allocation concealment, identifying
whether the trial was blinded, and whether intention-to-treat
analyses were available. After review of abstracted data, items were
grouped or redefined to combine and use data from the most
studies possible. Ratings for disease severity using Eastern
Cooperative Oncology Group or Karnofsky scales were converted
to the World Health Organization (WHO) scale. Where possible,
studies were characterised as to whether patients were identified
as ERþ and/or PRþ, and also HER2þ (ER/PR¼oestrogen
receptor/progesterone receptor; HER2¼human epidermal growth
factor receptor-2). Treatments were characterised as first-line or
subsequent (if any prior treatments for MBC) and grouped by drug
class. For simplicity, only two treatment groups were used from
each study. For studies that included three treatment groups, the
group with the highest efficacy compared with control or the
highest group from dose-ranging studies was included. Treatment
groups were reviewed by two clinicians and identified, to the best
extent possible, as an experimental treatment or a more standard
treatment.
All studies provided at least the median overall survival and
median TTP/PFS per study arm. We abstracted effect sizes and
variances, where available. Hazard ratios and s.e. were not
consistently available, and variances could not be calculated for
all studies. For this reason, we show regression models weighted by
sample size.
Data analysis
Although few studies reported hazard ratios (HR), we derived it as
the ratio of median times to event for the two treatment groups,
under the assumption that survival follows an exponential
distribution (Hackshaw et al, 2005). HRs were computed for
experimental treatment vs standard treatment. The estimates for
HRTTP and for HROS were each centred at unity, so that the
treatment effects for each outcome were defined as:
Table 1 Published meta-analyses in multiple tumour types
Tumour
type Studies included Reference Relationship analysed
Number of
studies
Slope
coefficient R
2
Breast:
metastatic
All randomised studies reporting
progression and survival times by
treatment
Current
analysis
Ratio of median progression and
ratio of median survival times
(centred at zero)
67 0.32 0.30
Breast:
metastatic
Studies of anthracyclines and taxanes
with individual patient data
Burzykowski et al
(2008)
Log hazard ratio for progression
and log hazard ratio for survival 11
Not provided
0.23
Breast:
metastatic
Studies of epirubicin regimens with
individual patient data
Bruzzi et al
(2005)
Log hazard ratio for response and
log odds ratio for survival 10
Not provided
0.10
Breast:
advanced
Studies of first-line treatments using
FAC or FEC
Hackshaw et al
(2005)
Log hazard ratio for time-to-progression
and log hazard ratio for survival
17 before
1990
0.58 before
1990
0.67 before
1990
9 after
1990
0.40 after
1990
0.41 after
1990
Breast:
adjuvant
Studies reporting 2- to 3-year disease-
free
survival and 5-year overall survival
(NX100)
Ng et al
(2008)
Difference in proportion with
disease-free survival at 2 years and
difference in proportion surviving
45 years
126
Not provided
0.38
Colorectal:
advanced
Studies of FU+leucovorin with
individual patient data
Buyse et al (2007) Log hazard ratio for progression-
free survival and log hazard ratio
for survival
10 0.81 0.98
Colorectal:
metastatic
Studies with ‘mature data’ (NX100) Tang et al (2007) Hazard ratio for progression
and hazard ratio for survival 39
Not provided 0.55 (PFS)
0.27 (TTP)
Colorectal:
metastatic
Studies of first-line treatments Johnson et al
(2006)
Difference in months-to-progression and
difference in survival months 146 0.096 0.33
Colorectal:
metastatic
Studies of first-line treatments
(NX100 per arm)
Louvet et al (2001) Median months progression-free survival
and median months
survival by treatment group
29 0.68 0.23
Colon:
adjuvant
Studies selected based on ‘relevance,
maturity and data availability’
(individual patient data)
Sargent et al (2005) Hazard ratio for disease-free survival and
hazard ratio for survival 18 0.89 0.90
Lung (non-
small-cell)
Studies reporting hazard ratios since
1977
Johnson et al
(2004)
Log hazard ratio for time-to-progression
and log hazard ratio
for survival
48 Not provided 0.42
Lung:
metastatic
Studies of first-line treatments Johnson et al
(2006)
Difference in months-to-progression and
difference in survival months 191 0.62 0.19
R
2¼coefficient of determination for multivariate analysis or derived as squared correlation coefficient.
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sEffectTTP¼HRTTP 1
EffectOS¼HROS 1
Using traditional meta-regression techniques, each study was
analysed as a unit. Modeling by study provides a test for the
association between each effect size for progression and effect size
for survival. In other words, the model tests whether a study that
shows differentiation between groups on the progression outcome
is expected to show differentiation between groups on survival.
The basic model structure for the meta-regression is:
EffectOS i¼b1 EffectTTP iþe
where each study (i) contributed one observation to the meta-
regression, weighted by sample size. Note that the intercept is
forced to equal zero to reflect the plausible assumption that
treatments with no effect on TTP will have no effect on survival.
Preliminary modeling justified the choice of no intercept. For
computing prediction intervals associated with different values of
EffectTTP, an intercept term was included so that perfect prediction
at the no effect point was not assumed. Average survival time was
considered as a covariate, but it was not significant, did not affect
inferences, and was removed for ease of presentation. Exclusion of
outliers did not affect inferences, so all studies were retained in the
analyses. Subgroups of clinical interest were modeled separately
for ease of interpretation. All analyses were performed using SAS
version 9.1.
RESULTS
The electronic literature search was conducted using PubMed on
11 October 2007. Data flow is shown in Figure 1 and study data is
presented in Appendix 1. Two articles represented data from the
same clinical trial (Eiermann, 2001; Slamon et al, 2001), and three
of the 71 abstracted articles were subsequently excluded because
they used high-dose chemotherapy, which has limited application
to current clinical practise (Lotz et al, 2005; Schmid et al, 2005;
Kro ¨ger et al, 2006). The resulting 67 clinical trials represent 17081
patients. All trials were randomised. One trial was placebo-
controlled and two allocated the control group to observation or
usual care. Blinding was identified for only two trials. In 37 trials,
analyses were identified as intent-to-treat; other trials did not
specifically state intent-to-treat approach.
Most trials required patients at entry to be rated as WHO Grade
2 or below for performance status; 11 studies allowed up to Grade 3
performance status. Median age was 55 years (range: 50–75 years).
Hormone status for patients was presented for 46 studies, ranging
from 14 to 84% oestrogen and/or progesterone receptor (ER/PR)
positive. Only six studies provided HER2 (human epidermal
growth factor receptor-2) status, four of which included only
HER2þ patients. Most studies were of first-line treatment for
MBC (46 studies); some of these studies allowed prior adjuvant
treatment, but not prior chemotherapy for MBC. A range of drug
classes were represented in 28 studies of monotherapies and 39
studies of combination regimens as shown in Tables 2 and 3.
The unweighted median TTP/PFS averaged across all treatment
groups was 7 months (range, 2–15 months), and the average
survival time was 20 months (range, 8–38 months). Correlation
was 0.38 between time-to-progression and survival in the separate
treatment groups (that is, ignoring trial comparisons).
Of 31 studies that provided tests of treatment differences for
both TTP/PFS and OS, there was a moderate agreement between
outcomes (Kappa test for agreement¼0.47, Po0.05). About half of
these studies (48%) had a significant effect on progression, but
only 23% had a significant effect on survival. None of the studies
reported a significant effect on survival if there was not a
significant effect on progression.
Figure 2 shows HROS vs HRTTP for all studies with the radius of
the bubbles representing relative study sample sizes. The range of
HRTTP for comparing experimental to standard treatments was
0.5–1.9; HROS ranged from 0.4 to 1.6. Minimal effects on both
progression and survival were seen in 13% of studies; that is, the
hazard ratio for both end points was close to one (0.9 oHR o1.1).
In 39% of studies, treatment effects on both progression and
survival were greater than 10% and in the same direction. Other
within trial treatment comparisons gave mixed results on the two
end points. In many studies, the hazard ratios showed a treatment
effect on progression with minimal effect on survival (30%); fewer
studies resulted in hazard ratios representing a minimal effect on
progression with a more pronounced effect on survival (13%). In
the very few studies with discordant results on treatment effect
(that is, HRRTTP and HRROS in opposite directions, shown in upper
left and lower right quadrants of Figure 2), no pattern was apparent
in terms of treatment or patient types. The unweighted Pearson
correlation between HRTTP and HROS across trials was 0.46.
The regression line shown in Figure 2 corresponds to the
primary model results shown in Table 4. If the slope coefficient
in this model equals zero (b¼0), then the treatment effect on
progression is not expected to affect treatment difference in
survival; if b¼1, treatment effects on survival are expected to
mirror treatment effects on progression end points. For 0o b o1,
we would expect that a treatment effect on progression is
Articles identifed
N=640
Excluded: not RCT
N=422
Excluded: not English,
abstract only or duplicate
N=20
Excluded: survival or
progression details missing
N=29
Abstracted
N=71
Included studies
N=67
Excluded: not all MBC
N=98
Figure 1 Flow diagram of literature search.
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analysis, we found b1¼0.32 (95% CI: 0.20, 0.43) supporting the
last interpretation (R
2¼0.30). Results did not suggest curvature in
the relationship (quadratic term, P¼0.16). Adding an intercept
term had only a minor effect on the slope parameter. The model
predicts that a treatment effect on HR for progression equal to 0.70
would translate into a hazard ratio for survival of 0.88 (Table 5).
Note that the confidence intervals shown in Table 5 are based on
modelling the meta-analysis data and are not intended for trial
planning purposes; the width of the interval will be dependent on
the sample size of future trials.
In studies of hormonal agents, the regression had a steeper slope
with a wide CI encompassing one (b1¼0.58; 95% CI: 0.001, 1.17;
Table 4). Results in subsets of anthracycline studies, first-line
treatments and later treatments were similar to the overall analysis.
In four studies in which all patients were identified as HER2þ, the
slope was 0.50 but the CI did not encompass one. In this group of
studies, the correlation between end points was particularly strong
(R
2¼0.93).
Several additional subset analyses were performed in an effort to
determine if patient characteristics or study type affected results.
Studies in which progression was delayed by at least 6 months in
the standard group might represent patients with better prognosis
than in the overall group of studies. However, analysis of this
group of studies and analysis of studies with at least 100 patients
per group were very similar to the overall analysis.
We also reran the overall analysis with indicators for blinding
and availability of ITT results. Neither had a significant effect on
the regression (P¼0.77 and 0.36 respectively), nor did the
parameter estimate for the slope of the progression end point
change appreciably. The fact that a study reported HRs is another
potential indicator for study quality. HRs from proportional
hazards modeling properly account for censored data and may
have incorporated additional covariate effects; the reported values
provide the best effect estimates from each study. For the 10
studies that reported hazard ratios, the reported HRTTP corre-
sponded more closely with HROS (slope¼0.52) than in the overall
analysis using derived HRs and more of the variability was
accounted for by the model (R
2¼0.52).
Additional exploratory analyses using different configurations
of the outcome variable (difference in survival months, logarithm
of the hazard ratio, analysis on survival months from separate
Table 2 Treatment types in included studies of monotherapies (n¼28)
Experimental monotherapy
Comparator Anthracycline Chemotherapy Hormonal agent Taxane Biologic Other
Anthracycline 4 2
Chemotherapy 1 4
Hormonal agent 10
Taxane 3
Biologic 1
Placebo or usual care 1 1 1
Table 3 Treatment types in included studies of combination therapies (n¼39)
Experimental combination regimens
Comparator
Anthracycline+
taxane
Anthracycline+
chemotherapy
Anthracycline+
hormonal agent
or biologic
Multiple
anthra-
cyclines
Multiple
chemo-
therapies
Chemo-
therapies+
Other
Multiple
hormonal
agents
Biologic+
Chemotherapy
or taxane
Anthracycline+taxane 4
Anthracycline+
chemotherapy
651 2
Anthracycline+
other
1
Anthracycline 3 1 2
Chemotherapy 4 3 2 1
Hormonal agent 1
Taxane 1 1
Biologic+taxane 1
2.0
1.5
1.0
0.5
H
R
R
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HRR for progression
0.0
0.0 0.5 1.0 1.5 2.0
Figure 2 Plot of HR for survival vs HR for progression by study size
regression line: EffectOS¼0.32 EffectTTP where Effect is the HR centred
at unity. Bubbles show relative sample sizes from each study.
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the models shown here.
DISCUSSION
These results demonstrate a clear positive association between
effects on progression and survival in MBC patients, which is
statistically significant. The analyses suggest that a treatment that
prolongs time-to-progression will likely also have a longer overall
survival time than the alternate treatment, although the relative
effect will be substantially smaller. The analysis suggests that
additional survival time seems to occur prior to progression and
be a direct result of delaying this event; however, we did not have
adequate data to look specifically at survival after progression.
The plot of effects on progression and survival illustrates the
wide heterogeneity of results across studies conducted in
metastatic breast cancer patients. In our analyses, we saw the
highest level of predictability when analysing only the small subset
of studies, which were conducted in HER2þ patients. Whether
this finding is because of the similar design, homogeneous patients
or treatment comparisons in these four studies remains in
question. We note that the R-squared term (coefficient of
determination) represents the amount of variance explained by
the regression model and provides a measure of how reliably
progression effects can predict survival effects. In other words, it
measures the reproducibility of the relationship and is dependent
both on the validity of the model and the sample size of the
individual studies. On the other hand, the slope parameter (beta
estimate) from the model quantifies the size of the effect, allowing
one to ascertain how changes in progression effects will translate
into changes in survival effects. In all the analyses presented here,
we found a slope parameter that is statistically greater than zero
(lower bound of CI is greater than zero). The relative survival effect
is expected to be about one-third of the relative effect on
progression.
Conducting a meta-analysis of time-to-event data from pub-
lished reports is difficult as appropriate summary statistics are not
always available in the publications. In practise, meta-analysis is
constrained by data availability, often suffers from lack of power,
and may not adequately capture the effects of patient character-
istics. For this analysis, we made decisions regarding outcome
selection, weighting and model building that allowed us to
incorporate the most studies. Results should be viewed as
hypothesis-generating, rather than confirmatory. Specific limita-
tions related to reporting include the following:
(a) Inclusion criteria and individual patient characteristics of
prognostic importance may have varied across studies. Thus,
homogeneous groups or subgroups of patients cannot be
readily identified.
(b) Studies had somewhat inconsistent definitions for progression
end points. Methods of assessing progression and specifics
about how progression itself was defined were not examined.
(c) Consistent summary statistics (for example, hazard ratios and
variance) were not available for all trials making more detailed
analyses impossible.
(d) Few studies clearly identified treatment options such as
crossover after progression.
Although it seems almost obvious that progression-free survival
should be correlated with overall survival, the link between delayed
progression of MBC from anticancer drugs and survival benefit is
not well established. The goal of this investigation was to explore
the extent to which progression end points can provide a reliable
surrogate for OS in trials conducted in women with metastatic
breast cancer. Although reducing death from breast cancer must
be the primary goal of clinical trials, use of OS as a primary end
point has several problems. In particular, (1) there is no control of
treatment options after progression has taken place, (2) survival
results are delayed as progression precedes death by several years
on average even in metastatic breast cancer, and (3) deaths from
causes other than breast cancer may occur. All of these factors can
dilute real treatment effects on breast cancer survival in these
women. These diluting factors make it hard to confirm the link
between effects on progression and effects on survival.
Results presented here are generally consistent with findings in
other tumour types (Table 1), although the different analysis
approaches and inclusion criteria make it difficult to compare
results across the literature. In breast and other tumour types, the
highest predictive power was achieved when meta-analyses were
performed using individual patient data on a small group of trials
(Sargent et al, 2005; Buyse et al, 2007). Hackshaw et al (2005)
noted an association between treatment effects on progression and
survival when comparing anthracycline-based regimens in ad-
vanced breast cancer and suggested use of time-to-progression as a
surrogate marker for survival. Interestingly, they found a stronger
relationship between the end points in studies performed prior to
1990 when second-line therapies for metastatic cancer were not
commonly used. More recently, a meta-analysis of 11 studies in
Table 4 Summary of regression analyses
a
Number of studies Slope parameter estimate (95% CI) R
2 (adjusted)
Primary model – all studies 67 0.32 (0.20, 0.43) 0.30
Studies of hormonal treatments 12 0.58 (0.001, 1.17) 0.24
Studies of anthracyclines 36 0.32 (0.19, 0.43) 0.43
Studies of first-line treatments for MBC 46 0.29 (0.15, 0.42) 0.28
Studies of non first-line treatments 21 0.38 (0.14, 0.62) 0.32
Studies with only HER2+patients 4 0.50 (0.28, 0.71) 0.93
Studies which reported HRs 10 0.52 (0.18, 0.86) 0.52
Studies where TTP in standard group X6 months 37 0.32 (0.18, 0.47) 0.35
Studies with N per group X100 36 0.31 (0.16, 0.47) 0.31
CI¼confidence interval.
aModels without intercept and weighted by sample size.
Table 5 Predicted HROS based on observed HRTTP
Observed HRTTP Predicted* HROS
0.5 0.82 (0.76, 0.88)
0.6 0.85 (0.80, 0.90)
0.7 0.88 (0.84, 0.92)
0.8 0.91 (0.87, 0.95)
aUsing model Effect OS¼ 0.03+(0.30 *Effect TTP).
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smetastatic breast cancer comparing anthracyclines to taxanes
examined the association of several end points with survival
(Burzykowski et al, 2008). The researchers found tumour response
to be more highly associated with overall survival than was
progression-free survival. However, that meta-analysis appears to
be unweighted. Our weighted analysis of anthracycline studies
produced an R
2 value almost double that reported by Burzykowski
et al (2008). Using sample sizes as weights, we show a moderately
strong linear correlation between progression-free survival and
survival, in a large group of studies covering many treatment
types. We find it intriguing that the strength of the relationship
between end points may vary by tumour and/or treatment types
and by line of therapy.
The consistency of findings in this comprehensive meta-analysis
shows that we can expect overall survival with metastatic breast
cancer to be extended when tumour progression is delayed,
although the effect size will typically be smaller. The attenuated
effect is due at least partly to the diluting factors indicated above
and suggests that overall survival itself is not a perfect end point
for assessing the value of a treatment. We do not believe
that the current findings are sufficient for accepting time-to-
progression as a fully validated surrogate marker for overall
survival in MBC, as the variance in the relationship is not fully
explained. Factors that could improve the prediction remain
under investigation. Nonetheless, the evidence suggests that
progression is a useful early end point that should feature
prominently in assessments of treatment efficacy for MBC. Further
work is needed to better understand what determinants are
associated with the link between disease progression and breast
cancer survival and whether some tumour and/or treatment
subgroups experience a more substantial survival benefit from
delayed progression.
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Appendix 1 Table of studies and treatments showing median months to progression (TTP or PFS) and overall survival (OS)
First author Reference Standard treatment N TTP OS Experimental treatment N TTP OS
Abrams J Clin Oncol 1999;17:64–73. Megestrol acetate 160mg/d 124 8.3 27.8 Megestrol acetate 800mg/d 120 8.1 28.6
Ackland J Clin Oncol 2001;19:943–53. CMF 223 6.3 18.2 CEF 237 8.7 20.1
Alba J Clin Oncol 2004;22:2587–93. Concomitant doxorubucin+docetaxel 6
cycles
69 9.2 21.8 Sequential doxorubicin -4 docetaxel 3 cycles each 75 10.5 22.3
Bastholt J Clin Oncol 1996;14:1146–55. Epirubicin 40 76 4.4 13.6 Epirubicin 90 71 8.4 14.6
Batist J Clin Oncol 2001;19:1444–54. Doxorubicin+cyclophosphamide 142 5.5 16 Myocet (liposome encapsulated doxorubicin) 155 5.1 19
Becher Semin Oncol 1996;23:28–33. Continued epirubicin/ifosfamide 63 5.4 13.5 Discontinued 60 3.2 13.2
Beex Eur J Cancer 2006; 42: 3178–3185 Continuous tamoxifen 94 11 35.1 Intermittent tamoxifen 93 8 35.2
Berruti J Clin Oncol 2002;20:4150–9. Epirubicin+cisplatin 185 10.9 28.8 Epirubicin+lonidamine 186 10.8 29.8
Bezwoda Oncology 1998;55:416–20. megestrol acetate 40mg qid 46 4.18 26.18 Fadrozole 50 3.98 20.46
Biganzoli J Clin Oncol 2002;20:3114–21. Doxorubicin+cyclophophamide 138 6 20.5 Doxyrubicin+paclitaxel 135 6 20.6
Bishop J Clin Oncol 1999;17 :2355–64. Cyclophosphamide 107 6.4 13.9 Paclitaxel 102 5.3 17.3
Bonneterre Br J Cancer 2004;91:1466–71. Epirubicin 75+5-FU 500+cyclophosphamide
500
70 5.9 28 Epirubicin 75+docetaxel 75 72 7.8 34
Bonneterre Br J Cancer 2002;87:1210–5. 5-FU 750+vinorelbine 25 88 5.1 15 Docetaxel 100 90 6.5 16
Bontenbal J Clin Oncol 2005;23:7081–8. FAC 109 6.6 16.2 Doxyrubicin+docetaxel 107 8 22.6
Bontenbal Br J Cancer 1998;77:2257–63. Doxorubicin 75 118 5.75 11.75 Epirubicin 90 114 4.75 11
Brufman Ann Oncol 1997;8:155–62. Standard FEC (epi 50) 214 7 17 Intensive FEC (epi 100) 242 7.6 18
Byrne J Clin Oncol 1997;15:3141–8. Tamoxifen+medroxy progesterone 109 3 17.2 Medroxyprogesterone only 106 4.5 18.4
Capotorto J Chemother 2003;15:184–91. FEC 45 12.7 23.3 MMM-G (time intensified) 46 14.5 24.1
Chan Ann Oncol 2004;15:1527–34. Epirubicin+C 80 5.6 16 Myocet(liposome-encapsulated doxoorubicin)+C 80 7.7 18.3
Chan Breast Cancer Res Treat 2004;86:197–206. Doxorubicin 50 161 5.25 14 Docetaxol 100 165 6.5 15
Cocconi Am J Clin Oncol 1999;22:593–600. CONVENTIONAL CMF (cyclophosphamide,
methotrexate, 5-FU)
53 15 27.25 Rotational crossing program 53 9.75 23
Conte Ann Oncol 1996;7:487–90. CEF 128 9.4 17.3 Diethylstilbestrol +CEF 130 11 20
Conte Cancer 2004;101:704–12. Concommitant epirubicin and paclitaxel 106 11 20 Sequential epirubicin and paclitaxel 92 10.8 26
Dogliotti J Clin Oncol 1996; 14:1165–72. Epirubicin 104 10.6 25.3 Epirubicin+lonidamine 103 10.5 25
Ejlertsen J Clin Oncol 2004;22:2313–20. Epirubicin 194 8.2 18 Epirubicin+vinorelbine 193 10.1 19.1
Elomaa Ann Oncol 2003;14:699–703. Vinorelbine 20 (+methotrexate and
fluorouracil)
26 7 26 Vinorelbine 30 +MF 10 8 16
Estaban Breast Cancer Res Treat 1999;58:141–50. Cyclophosphamide+fluorouracil+epirubicin
(CEF)
76 12.75 18.6 Cyclophosphamide+fluorouracil+mitoxantrone
(CNF)
75 8.25 12.85
Fountzilas J Clin Oncol 2001;19:2232–9. Epirubicin +paclitaxel 93 8.5 20 Epirubicin 4cycles THEN paclitaxel 4cycles 90 10 21.5
Fountzilas Ann Oncol 1997;8:1213–20. Epirubicin every 4 weeks+filgastim 81 7.2 14.6 Epirubicin every 2 weeks+filgastim 86 7.4 14.9
French Epirubicin
Study Group
J Clin Oncol 2000;18:3115–24. FEC 75 11 cycles 139 10.3 17.9 FEC 100 4 cycles+FEC 50 8 cycles 133 6.2 16.3
Gennari J Clin Oncol 2006; 24: 3912–3918 Control 109 9 29 Paclitaxel 106 8 28
Gershanovich Ann Oncol 1998;9:639–45. Aminoglutethimide 250mg 192 3.2 20 Letrozole 2.5mg OD 178 3.4 28
Goss J Clin Oncol 1999;17:52–63. Megetrol acetate 40mg QID 225 3.3 28.8 Vorozole 2.5mg OD 227 2.6 26.3
Gregory Eur.J Cancer 1997;33:2194–7. Stop current treatment (VAC, VEC or MMM)
after six courses
52 7 10.5 Continue current treatment for 12 courses 48 10 13
Hausmaninger Eur.J Cancer 1995;31A:2169–73. Epirubicin – vindesine 149 5.4 14.7 Mitoxantrone – vindesine 146 5.1 13.3
Hayes J Clin Oncol 1995;13:2556–66. Toremifene 60mg/d 212 5.6 38.3 Toremifene 200mg/d 221 5.6 30.1
Heidemann Ann Oncol 2002;13:1717–29. Mitoxantone 12 127 4.4 14.1 Flourouracil 500+epirubicin 50+
cyclophosphamide 500 (FEC)
133 6.15 15.8
Ingle Cancer 1994;73:2337–43. CMF 80 4.1 13.3 CMF preceded by diethylstilbestrol 83 4.3 12.4
Jassem J Clin Oncol 2001;19:1707–15. FAC 134 6.2 18.3 Doxorubicin+paclitaxel 133 8.3 23.3
Joensuu J Clin Oncol 1998;16:3720–30. Epirubicin 20 weekly then mitomycin every
4 weeks
153 8 16 CEF 3 week then mitomycin+vinblastin 150 10 18
Jones J Clin Oncol 1995;13:2567–74. Alkeran (melphalan) 115 2 7.75 Navelbine (vinorelbine) 64 3 8.75
Kaufman
a Clin Breast Cancer 2000;1 Suppl 1:S15-S18. Megestrol acetate 40mg/d 366 4.15 13.75 Exemestane 25mg/d 403 5.08 18.65
Kloke Breast Cancer Res Treat 1999;55:51–9. No treatment 46 3.9 18.3 Medroxy progesterone acetate 44 4.9 17.4
Langley J Clin Oncol 2005;23:8322–30. Epirubicin+cyclophosphamide 353 7.1 14 Epirubicin+paclitaxel 352 7 13
Marty J Clin Oncol 2005;23:4265–74. Docetaxel 94 6.1 22.7 Trastuzumab+docetaxel 94 11.7 31.2
Miller J Clin Oncol 2005; 23:792–9. Capecitabine alone 230 4.17 14.5 Capecitabine 2,500 bd+bevacizumab 15mg/kg 232 4.86 15.1
Muss J Clin Oncol 1994;12:1630–8. Medroxy progesterone acetate 91 8.1 33 Tamoxifen 20mg /d 91 5.9 23.8
Nabholtz J Clin Oncol 1999;17:1413–24. Mitomycin 12+vinblastine 6 203 2.75 8.7 Docetaxel 100 189 4.75 11.4
Nabholtz J Clin Oncol 2003;21:968–75. Doxorubicin 60+cyclophosphamide 600 214 7.98 21.7 Doxorubicin 50+docetaxel 75 215 9.325 22.5
Nabholtz J Clin Oncol 1996;14:1858–67. Paclitaxel 135 235 3 10.5 Paclitaxel 175 236 4.2 11.7
Namer Eur J Cancer 2001;37:1132–40. Mitoxantrone+vinorelbine 138 7 17 FAC or FEC 142 7 20
Nooij Eur J Cancer 2003;39:614–21. Continue CMF 97 5.2 14 Stop CMF (and restart in the case of progression 107 3.5 14.4
Norris J Clin Oncol 2000;18:2385–94. Doxorubicin alone 151 6.1 14.4 doxorubicin+vinorelbine 149 6.2 13.8
O’Brien Ann Oncol 2004;15:440–9. Doxorubicin 254 7.8 22 Caelyx (PLD) 255 6.9 21
Pacilio Br J Cancer 2006;94:1233–6. Docetaxel 100 25 11 21 Docetaxel 80+epirubicin 75 26 9 18
Paridaens J Clin Oncol 2000;18:724–33. Doxorubicin 166 7.5 18.3 Paclitaxel 165 3.9 15.6
Pavesi Anticancer Res 1995;15:495–501. FNC 78 7.5 15.5 FEC 74 8.5 19
Peethambaram Breast cancer Res Treat 1999;54:117–22. Diethylstilbestrol 69 6.9 36 Tamoxifen 74 5.9 28.8
Perez Ann Oncol 2002;13:1225–35. AC THEN docetaxel 17 10.2 13.2 Docetaxel THEN AC 16 12 30
Robert J Clin Oncol 2006;24:2786–92. TP (trastuzumab and paclitaxel) 98 7.1 32.2 TPC (trastuzumab, paclitaxel and carboplatin) 98 10.7 35.7
Rose Breast Cancer Res Treat 2000;61:103–10. Tamoxifen+fluoxymesterone 86 9.2 21.1 Tamoxifen+aminogluthimide+hydrocortisone 86 7.7 24.1
Sjostrom Eur J Cancer 1999;35(8):1194–1201. Sequential methotrexate and 5-FU 143 3 11 Docetaxel 100 140 6.3 10.4
Slamon N Engl J Med 2001;344:783–92. Standard chemotherapy 234 4.6 20.3 Standard chemotherapy+trastuzumab 235 7.4 25.1
Sparano J Clin Oncol 2004;22:4683–90. Placebo 69 3.1 26.6 Marimastat 120 4.7 24.7
Tabernero Ann Oncol 2004;15:1358–65. Docetaxel 3-weekly 41 5.3 20.1 Docetaxel weekly 42 5.7 29.1
Vogel J Clin Oncol 2002;20:719–26. Trastuzumab 4mg/kg loading+2mg/kg weekly 59 3.5 22.9 Trastuzumab 8mg/kg loading+4mg/kg weekly 55 3.8 25.8
Winer J Clin Oncol 2004;22:2061–8. Paclitaxel 175 158 3.9 11 Paclitaxel 210 155 4.9 14
Abbreviations for treatments: A¼Adriamycin (doxorubicin); C¼Cytoxan (cyclophosphamide); E¼epirubicin; D¼docetaxel; F¼5-FU; V¼vinorelbine. Acronyms for
combination regimens: AC¼doxorubicin+cyclophosphamide; CMF¼cyclophosphamide+methotrexate+5-FU; FAC¼5-FU+doxorubicin+cyclophosphamide; FEC¼
5-FU+epirubicin+cyclophosphamide(also called CEF); FNC¼5-FU+novantrone+cyclophosphamide; MMM¼mitoxantrone+methotrexate+mitomycin-C; TP¼trastumuzab+
paclitaxel.
aOS provided at 25th percentile.
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